Peter C. Richardson - 10 Jun 2021 Form 4 Insider Report for ANTARES PHARMA, INC. (ATRS)

Role: EVP, R&D Chief Medical Officer
Signature: /s/ Lisa M. Kallebo as attorney-in-fact for Peter C. Richardson
Issuer symbol: ATRS
Transactions as of: 10 Jun 2021
Transactions value $: $160,000
Form type: 4
Filing time: 14 Jun 2021, 18:25:06
Next filing: 26 May 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ATRS	Common Stock	Award	$160K	+36.2K		$4.42	36.2K	10 Jun 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ATRS	Stock Option (right to buy)	Award	$0	+69K		$0.00	69K	10 Jun 2021	Common Stock	69K	$4.42	Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents grant of restricted stock units made under the Antares Pharma, Inc. Equity Compensation Plan. The shares vest in three equal annual installments from the date of grant.
F2	Represents grant of options to purchase shares of common stock, par value $0.01 per share, issued under the Antares Pharma, Inc. Equity Compensation Plan.
F3	The options vest and become exercisable in three equal annual installments on the first, second and third anniversaries of the grant date.